pharma · Symptomatic hypertrophic cardiomyopathy (HCM) · SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Cytokinetics
Cytokinetics (Ireland) Limited
Cytokinetics (Ireland) is a pharma organization headquartered in GB. Primary therapeutic focus areas include Symptomatic hypertrophic cardiomyopathy (HCM), SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY, Heart Failu
South San Francisco, USA HQ
1998 Founded
759 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 1998
- Employees
- 759
- Programs
- 5
- Drugs
- 7
- Patents
- 0
CY 6023
Phase 3 · small molecule · SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
CY 6023 for SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY is a Phase 3 program (small_molecule) at Cytokinetics (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Internal code CY 6023
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Cytokinetics (Ireland) Limited
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
- Status
- active
- Trials
- 1